Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

2657
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

04/24/2012 | 03:39pm US/Eastern

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
React to this article
Latest news on SANOFI
05/06 ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results
05/06DJAlexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update
05/06 SANOFI : Pasteur Employee Honored with Marley's Mission Saddle of Hope Award
05/06 SANOFI : Merial Assigned Patent
05/05 SANOFI : Majority of Canadians unprepared for an allergy emergency. Team Allerje..
05/04DJGeneric Drugs Grab Growing Market Share in Mexico--Update
05/04DJGeneric Drugs Grab Market Share in Mexico
05/04 SANOFI : Health and Human Services Department (HHS); Food and Drug Administratio..
05/04 SANOFI : Annual General Shareholder Meeting of May 4, 2015
05/03 GENZYME : Commences Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry D..
Advertisement
Chart
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF